Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 February 2025 | Story Andre Damons | Photo Supplied
Prof Carolina Pohl-Albertyn
Prof Carlien Pohl-Albertyn is the NRF SARChI Research Chair in Pathogenic Yeasts at the UFS.

A new study by researchers from the University of the Free State (UFS), the National Health Laboratory Service, and the University of Venda has confirmed for the first time that common brown locusts are carriers of pathogenic yeasts that can cause severe infections in humans – especially in people with compromised immune systems or who are seriously ill.

The study, ‘South African brown locusts, Locustana pardalina, hosts fluconazole resistant, Candidozyma (Candida) auris (Clade III)’, highlights for the first time the presence of the pathogenic (disease-producing) fungal yeast C. auris in the digestive tract of the locusts, and shows their potential in disseminating this emerging pathogen. The research started in April 2022, when 20 gregarious (swarming) adult locusts were collected during a large locust outbreak which occurred from September 2021 to May 2022 in the semi-arid Eastern Karoo region in the Eastern Cape. The study is still under peer review.

According to Prof Carlien Pohl-Albertyn, National Research Foundation (NRF) SARChI Research Chair in Pathogenic Yeasts, three C. auris strains were isolated from three different adult locusts, two of which also harboured strains of another potentially pathogenic yeast, Candida orthopsilosis. “The fact that we were able to isolate C. auris from 15% of the sampled locusts, using non-selective media and a non-restrictive temperature of 30°C, may indicate that C. auris is abundant in the locusts and that specific selective isolation is not mandatory,” Prof Pohl-Albertyn said.

“Interestingly, C. auris was isolated from the fore- and hindgut of the locusts. Isolation from the foregut, which is dedicated to food intake and storage, filtering and partial digestion, indicates that C. auris was probably obtained by the locusts via feeding activities. Isolation from the hindgut confirms that C. auris can survive the digestive processes in the midgut and is likely to be released back into the environment via faeces.”

Healthy humans are not at great risk

One of the C. auris strains was studied in more detail. This strain was not resistant to disinfectants but showed decreased susceptibility to the common antifungal drug fluconazole. This is a characteristic of this yeast species and thus not surprising. Most of the emerging pathogenic yeasts show this intrinsic resistance. This highlights the urgent need to discover and develop new antifungal drugs.

Prof Pohl-Albertyn, also a Professor of Microbiology in the UFS Department of Microbiology and Biochemistry, says, “Healthy humans are not at great risk for infection by this yeast and there is currently no proof that ingestion may be harmful to them. This is unfortunately not the case for people with compromised immune systems or who are seriously ill. However, few susceptible people come into direct contact with the locusts in South Africa.”

She added that there are treatment options available, using other antifungal drugs, but C. auris can become resistant to all the currently available antifungal drugs.

Importance of the study

“The fact that locusts are a food source for other animals, such as birds, could lead to eventual distribution of the yeast to people. In other countries, wild locusts are a food source for humans and there more direct transmission may be possible,” Prof Pohl-Albertyn said.

She explained that this study tries to answer questions regarding the natural hosts of this emerging pathogen and how it may facilitate the spread of the pathogen to the rest of the environment. The study is one part of the puzzle regarding how new pathogens may emerge from the environment and spread to people.

“One of the questions in the field of pathogenic yeasts is how C. auris was able to emerge as a pathogen in several different countries in a relatively short period. It is well known as a hospital-acquired pathogen, but it is not known where in the environment it occurs naturally, and which environmental factors may have shaped its evolution and ability to cause human infections. This has implications for the prevention of the spread of this specific yeast species, as well as our preparedness for new pathogenic yeasts that may be emerging from the environment.”

News Archive

Great turnout for Hannes Meyer Symposium in Cardiothoracic Surgery
2017-05-05

Description: Hannes Meyer Symposium  Tags: Hannes Meyer Symposium

Symposium attendees watch attentively as
Dr Johan Brink demonstrated a MAZE procedure
with a pig’s heart.
Photo: Supplied

The University of the Free State’s Faculty of Health Sciences hosted the annual Hannes Meyer Symposium in Cardiothoracic Surgery. The symposium was organised by Prof Francis Smit, head of the department of Cardiothoracic Surgery at the UFS, with the support from the Society of Cardiothoracic Surgeons of South Africa and the European Association of Cardiothoracic Surgery (EACTS). Over the past 16 years this symposium has steadily been growing in stature and prestige leading to the resounding success that was this year’s event.

Medical advancements explored
The aim of the symposium is to provide an overview of the latest advances in Cardiothoracic Surgery and perfusion as well as providing hands-on training via simulation to trainees from South Africa and the rest of the African continent. Didactic lectures and papers by registrars were an integral component of the symposium. The South African community was represented by various heads of departments, trainees, senior specialists and perfusionists from all the training centres in the country. There were also delegates representing Uganda, Mozambique, Nigeria and Zambia.

Heart surgery off to new heights
Simulation in Cardiothoracic Surgery and Perfusion can be compared to airline pilots with high risk, with complex surgeries being first done in simulators before being attempted in the real world. The UFS is proud to have a state-of-the-art simulation facility, which was used to facilitate the programme.

The range of simulation was extensive and included simple procedural models to complex full theatre setups with Human Performance Models in perfusion that simulated crisis scenarios with the aid of computerised devices that react in real time to human intervention.

Industry support highly appreciated
This event was coordinated by Dr Jehron Pillay, senior registrar in the Department of Cardiothoracic Surgery and Marilee Janse van Vuuren, deputy-director clinical technology, in the department. This was the first time that such extensive simulation models were used in the programme and judging from the positive response received, it has certainly set the benchmark for all future events.

The event has received invaluable support over the years from EACTS that has selected Bloemfontein as the site of its African training programme as a result of the high level of training and education achieved here.

The academic discussions were chaired by Profs Marko Turina and Jose Pomar (past presidents of EACTS) and Pieter Kappetein (past secretary general of EACTS) who are extremely well known internationally for their contribution to advancing Cardiothoracic training and education.

Our guests from EACTS presented didactical lectures on research methodology, international randomised trials and discussed recent developments and controversies in cardiothoracic surgery.

Registrars from all South African units presented a thoracic and cardiac surgery paper from each unit highlighting specific disease conditions, moderated by heads of departments and the international panel.

An event of this magnitude requires significant financial support and the medical industry in South Africa stepped up to the plate in providing financial and logistical support in order to make it possible.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept